Carl Bjartmar, a former Genzyme (Sanofi SA) executive, has joined Wilson Therapeutics AB as chief medical officer. The company is developing treatments for Wilson’s disease which is a genetic disorder resulting in deficiencies in the production of a copper transporter.
Dr Bjartmar led clinical development of treatments for rare and neurological disorders at Genzyme. Prior to that, he worked in clinical development and neurology at Lundbeck A/S. He received his medical and PhD degrees from the University of Linkoping in Sweden.
Wilson Therapeutics announced the appointment on 22 July 2015.
Copyright 2015 Evernow Publishing Ltd